^
Association details:
| Biomarker: | HER-2 overexpression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Kanjinti (trastuzumab-anns) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
06/13/2019
Excerpt:
KANJINTI is a HER2/neu receptor antagonist indicated for:...the treatment of HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma….Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product...
Secondary therapy:
XP; FP
Source:
Published date:
05/16/2018
Excerpt:
Kanjinti should only be used in patients with metastatic gastric cancer (MGC) whose tumours have HER2 overexpression as defined by IHC 2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result.
Source:
Title:
Study of chemotherapy combined with ABP 980 in patients with advanced cancer of stomach or gastro-esophageal junction HER2-positive Studio di chemioterapia associata ad ABP 980 in pazienti con tumore dello stomaco o della giunzione gastro-esofagea avanzato HER2 positivo
Excerpt:
...Tumor HER2 overexpressing, as determined by local testing on a gastric or GEJ tumor specimen. ...
Trial ID:
